Xilio Therapeutics (XLO) Revenue (2024 - 2026)

Xilio Therapeutics has disclosed Revenue across 3 years of filings, most recently posting $12.6 million for Q1 2026.

• Revenue for Q1 2026 came in at $12.6 million, up 331.67% year-over-year; the trailing twelve-month figure through Mar 2026 was $53.5 million (up 476.71% YoY), and the FY2025 annual result was $43.8 million, up 589.88% from the prior year.
• Revenue came in at $12.6 million for Q1 2026 at Xilio Therapeutics, down from $13.7 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $19.1 million in Q3 2025 to a low of $1.7 million in Q4 2024.
• The 3-year median for Revenue is $5.5 million (2025), against an average of $7.8 million.
• Peak annual rise in Revenue reached 742.51% in 2025, while the deepest fall reached 242.98% in 2025.
• Xilio Therapeutics' Revenue stood at $1.7 million in 2024, then surged by 693.85% to $13.7 million in 2025, then dropped by 7.58% to $12.6 million in 2026.
• The last three Revenue figures came in at $12.6 million (Q1 2026), $13.7 million (Q4 2025), and $19.1 million (Q3 2025), per Business Quant data.